Clinical Trial Update: A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CellCept (mycophenolate mofetil) with reduced corticosteroids in generalized myasthenia gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myasthenia Gravis, Generalized | Phase 3 | Status: COMPLETED